Tuesday, 25 November 2014 00:12
Markss HLC Ltd, one of the leading healthcare companies in Sri Lanka along with their business partners Panacea Biotec India successfully launched ‘Vagacyte’ brand of Valganciclovir 450mg USP during a Continuous Medical Education program conducted by Sri Lanka College of Nephrologists on the topic of ‘Place of therapy in Solid Organ Transplant’ held at Cinnamon Grand Hotel recently.
The guest speaker for this event was Dr. Ashok Kriplani, MD, MNAMS, (Nephrologists), President, Indian Society of Organ Transplantation, Prof. and Head – Dept. of Nephrology, Bombay Hospital, Institute of Medical Sciences, India.
Dr. Ashok Kriplani stressed on the importance of maintaining prophylaxis treatments with Valganciclovir 450mg even at a condition of ‘No Symptoms’ on post KT (Kidney Transplant) patients to have a better quality of life.
Added to this most kidney specialists present stated that although the prophylaxis were so important for post KT patients, exorbitant prices was a main concern.
Spokesperson for Markss HLC Ltd, said that they were extremely pleased to launch this product; considering the dire need of the kidney patients at a cost almost 1/3 the price of the existing product in the market. This was concurring with Panacea Biotec Ltd’s continuous endeavour to provide high quality medicines at affordable pricing.
This will no doubt immensely reduce the financial burden on the patients as well as the country as a whole.